Dose Ranging Study of Pegylated Interferon Lambda in Patients With Hepatitis B and Positive for the Hepatitis B e Antigen
Status:
Completed
Trial end date:
2013-12-01
Target enrollment:
Participant gender:
Summary
At least 1 dose of pegIFNλ will be identified which is safe, well tolerated, and efficacious
for the treatment of chronic hepatitis B virus infection (CHB)
Amendment 7, Part B Sub Study: The primary purpose of this amendment is to obtain preliminary
data on the safety of pegylated interferon Lambda (Lambda) when administered in combination
with Entecavir(ETV) to patients with hepatitis E antigen-positive (HBeAg-positive) chronic
hepatitis B(CHB) infection employing a sequential therapy approach